Matrix metalloproteinase-1 rs1799750 polymorphism and glaucoma: A meta-analysis

Purpose: Several studies indicated that -1607 1G/2G (rs1799750) polymorphism in matrix metalloproteinase-1 (MMP-1) promoter was correlated with glaucoma susceptibility, but the results remain controversial. We performed a meta-analysis to assess whether rs1799750 confers glaucoma risk.

Methods: Eligible studies were retrieved by systematically searching Pubmed, Embase, Web of Science, and Chinese Biomedical database. The degree of correlation was expressed as odds ratios (ORs) and 95% confidence interval (CI). The measurements were pooled by fixed effect model or random effect model.

Results: This meta-analysis included five case-control studies involving 1261 patients with glaucoma and 1089 controls. The pooled results showed a significant association between rs1799750 and glaucoma under the homozygote (OR = 1.71, 95% CI 1.12–2.62, p = 0.014), recessive (OR = 1.64, 95% CI 1.20–2.25, p = 0.002), and allelic (OR = 1.35, 95% CI 1.05–1.72, p = 0.017) models. Subgroup analyses showed that the rs1799750 was significantly associated with primary angle closure glaucoma under homozygote (OR = 2.23, 95% CI 1.03–4.83, p = 0.043) and allelic (OR = 1.61, 95% CI 1.07–2.42, P = 0.021) models, while it was significantly associated with primary open angle glaucoma (OR = 1.64, 95% CI 1.05–2.56, p = 0.030) and exfoliation glaucoma (OR = 1.42, 95% CI 1.02–1.97, p = 0.036) under recessive models. No evidence of publication bias was detected.

Conclusions: Meta-analysis of existing data showed that rs1799750 may affect individual susceptibility to glaucoma. Nevertheless, more studies with large sample size and various ethnicities are warranted in light of the limited studies.